Why Klotho Is Becoming Longevity's Biggest Bet | Longevity News Roundup — Week 27, 2026

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine CRISPR heart therapies, AI-guided Alzheimer's care, GLP-1 ecosystem expansion, biological age testing, Klotho programs, and regenerative medicine.

• Scribe Therapeutics secured more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance two CRISPR-based gene editing therapies toward human trials. The one-time treatments, STX-1200 and STX-1400, target inherited cardiovascular risk factors with the goal of durably reducing genetically driven heart disease risk.
• Eli Lilly's LillyDirect and ŌURA announced a collaboration to support people using prescribed GLP-1 therapies by combining access to treatment with wearable-based behavioral support. The initiative integrates sleep, activity, readiness, and other biometric insights to help reinforce healthy habits alongside obesity care, without sharing user data between the companies.
• NeuroXT and Beth Israel Deaconess Medical Center (BIDMC) expanded their collaboration to explore how AI could help identify the right treatment for the right Alzheimer’s patient. The research aims to identify which patients are most likely to benefit from emerging Alzheimer's therapies using imaging that is already widely available.
• Generation Lab launched SystemAge 2.1, describing it as the first biological age test to offer dedicated female and male versions. The platform analyzes more than 460 biomarkers across 21 organ systems from a needle-free blood sample, adding sex-specific assessments and organ-level tracking to monitor responses to longevity interventions.
• GARM Clinic debuted what it describes as the world's first Klotho Longevity Residency, a four-day educational program focused on Klotho-based gene therapy and regenerative medicine. Hosted in Roatán, Honduras, the residency brings together clinicians and researchers to explore translational longevity therapies in a more flexible regulatory setting.
• LyGenesis received a research award to expand its regenerative medicine platform into type 1 diabetes, to support a thymus program exploring immune tolerance to pancreatic islet transplantation. The funding will support preclinical development of a novel approach for tolerance induction following allogeneic pancreatic islet transplantation for type 1 diabetes, according to the company.

----------

News & References:

• Scribe lands $25m to advance heart disease gene therapies → https://longevity.technology/news/scribe-lands-25m-to-advance-heart-disease-gene-therapies/
• ŌURA-LillyDirect collab highlights new GLP-1 care model → https://longevity.technology/news/oura-lillydirect-collab-highlights-new-glp-1-care-model/
• AI and Alzheimer’s: NeuroXT, BIDMC aim to personalize care → https://longevity.technology/news/ai-and-alzheimers-neuroxt-bidmc-aim-to-personalize-care/
• Generation Lab launches SystemAge 2.1 as the first gender-specific biological age test → https://longevity.technology/news/generation-lab-launches-systemage-2-1-as-the-first-gender-specific-biological-age-test/
• GARM Clinic debuts world’s first Klotho longevity residency → https://longevity.technology/news/garm-clinic-debuts-worlds-first-klotho-longevity-residency/
• LyGenesis wins research award to advance type 1 diabetes cell therapy → https://longevity.technology/news/lygenesis-wins-research-award-to-advance-type-1-diabetes-cell-therapy/